Coverage unlocks reimbursable AI plaque quantification, advancing coronary risk assessment in everyday cardiology practice. Highlights New permanent Category I CPT code 75577 for AI-enabled coronary plaque analysis took effect January 1, 2026 Major payers, including Aetna, alongside UnitedHealthcare, Cigna, Humana, and others, now cover AI-enabled coronary plaque analysis, extending access to tens of millions of commercially insured patients Circle’s FDA-cleared, on-premise cvi 42 |Plaque solution integrates directly into CCTA workflows, giving physicians hands-on control of AI plaque analysis and retains more of the plaque analysis reimbursement Calgary, Alberta – Circle Cardiovascular Imaging Inc. (Circle CVI), the market leader in cardiovascular imaging postprocessing, announced that clinical practices using its FDA 510(k)-cleared cvi 42 with AI-enabled plaque analysis solution are well positioned to benefit from newly activated reimbursement for AI-enabled coronary plaque analysis under permanent Category I CPT code 75577, effective January 1, 2026. Major insurance companies have also announced that they are also reimbursing the costs of this analysis. New Category I CPT Codes Now in Effect Beginning January 1, 2026, AIdriven quantification and characterization of coronary atherosclerotic plaque derived from coronary CT angiography (CCTA) is reimbursed under a permanent Category I CPT code, 75577, replacing prior Category III codes. This transition enables nationally valued payment for quantitative plaque assessment across hospital outpatient departments, imaging centers, and physician offices. Growing Payer Support for AI Plaque Analysis Major commercial payers, including Aetna, UnitedHealthcare, Cigna, Humana, and others, now cover AI-based quantitative coronary plaque analysis , extending access to tens of millions of commercially insured patients and building on prior Medicare coverage decisions. This expanding reimbursement is expected to accelerate adoption of CCTA-based plaque assessment. AMA/ACC Guidance on When to Use Plaque Analysis In December 2025, a major scientific statement published in the Journal of the American College of Cardiology : Cardiovascular Imaging provided consensus recommendations on how and when to use quantitative coronary plaque analysis (QCPA) in practice. Their recommendations stated that among patients who have visual evidence of plaque on coronary CTA, adding QCPA may be useful for enhancing risk assessment and guiding the initiation or intensification of preventive therapies. CCTA’s Emerging Role as a Primary CAD Modality Recent analyses from cardiovascular imaging experts highlight how CCTA, augmented by AI-enabled plaque analysis, is poised to become the foundational imaging modality for the diagnosis and management of coronary artery disease. As reimbursement stabilizes and technology matures, CCTA is increasingly viewed as the frontline test that can characterize both stenosis and atherosclerotic burden, informing preventive strategies long before invasive procedures are required. cvi42|Plaque: FDA-cleared, On-premise AI for Coronary Plaque cvi 42 |Plaque, cleared by the U.S. FDA in late 2025, is an on-premise, AI-enabled coronary plaque analysis module that integrates directly into existing cvi 42 and CCTA workflows. The software automatically segments the coronary lumen and vessel wall, quantifies plaque burden and composition, and generates structured lesion- and vessel-level metrics to support risk stratification, preventive therapy decisions, and revascularization planning. Because the solution runs locally, image data, AI processing, and reporting remain within the institution’s environment, giving physicians interactive control over contouring and final interpretation while allowing programs to retain a larger share of reimbursement compared with outsourced, cloud only services. Localized AI and Circle’s Elevate Pricing Advantage “With the new Category I CPT code for coronary plaque analysis now in effect, and the major insurance players reimbursing plaque analysis, the economics and clinical evidence are finally aligned,” said Chris Bazinet, Chief Commercial Officer at Circle CVI. “cvi 42 |Plaque gives practices an on-premise, FDA-cleared AI solution that fits directly into their existing CCTA workflows, enabling guideline consistent plaque reporting, improved risk stratification, and better capture of the reimbursement now available for quantitative coronary plaque analysis.” cvi 42 |Plaque is available as part of the broader cvi 42 platform for cardiac CT and MR. Clinical sites interested in implementing AI-enabled coronary plaque analysis can contact Circle to assess readiness, workflow integration, and revenue potential. - ENDS - About Circle Cardiovascular Imaging Circle Cardiovascular Imaging Inc. (Circle CVI) is a Canadian-based company founded in 2007 with a mission to develop innovative software solutions that enhance cardiovascular and cerebrovascular imaging analysis and ultimately improve patient care. Circle’s flagship platform, cvi 42 , delivers best-in-class image reading and reporting tools for quantitative and qualitative assessment of cardiac MR, cardiac CT, vascular CT, and neuro CT. At the core of Circle’s work is a relentless commitment to empowering healthcare providers with advanced, intuitive tools that lead to better healthcare outcomes. This passion for innovation, rooted in both medicine and technology, drives Circle’s global impact and fuels a culture of excellence. Today, millions of medical imaging exams each year—across 1,700+ hospitals in over 90 countries—are interpreted using Circle’s cvi 42 platform.​ For media inquiries, please contact: marketing@circlecvi.com

Highlights  The latest release of cvi42v6.4 focuses on workflow efficiency and leveraging artificial intelligence In-house post-processing speeds reporting time and captures more reimbursement Circle’s vascular capabilities expand with the addition of cvi42 | Vascular CT New business models increase the flexibility and accessibility for reporting physicians Calgary, AB – Circle Cardiovascular Imaging (Circle CVI) , the market leader in cardiovascular imaging post-processing will unveil its latest release at the Radiological Society of North America (RSNA) Annual General Meeting being held November 30 – December 4 in Chicago, IL. Circle CVI will demonstrate its newest release, cvi42v6.4. Radiology leaders know that efficiency, accuracy, and practice growth are non-negotiable. At RSNA 2025, Circle Cardiovascular Imaging invites you to experience the new cvi42 release - a solution engineered to grow your CCT and CMR business. What cvi42 can do for your practice: Reduce Reporting Times: Native integration with PowerScribeautomates transcription, minimizing error risk and freeing clinical teams to focus on interpretation rather than manual data entry. Accelerate Patient Care: In-house plaque analysis with cvi42 enables faster turnaround times, supporting timely diagnosis and allowing you to deliver a higher standard of care. Drive Confidence and Adoption: cvi42 | Vascular CT follows best practices with automated contouring, lowering barriers to using advanced CT vascular analysis - so teams adopt new capabilities faster. Increase Revenue Capture: With cvi42 | Plaque you pay for what you process at a fraction of the price of outsourcing and increase your throughput with a streamlined workflow. Elevate Value and Flexibility: Our new subscription model provides scalable access to CMR and CCT functionalities ensuring your team has unlimited access to work from anywhere. “With our latest cvi42 release, we’re helping practices unlock greater efficiency, deliver faster patient care, and build a scalable foundation for the future of cardiovascular imaging while supporting business growth” said Chris Bazinet, Chief Revenue Officer of Circle CVI. “We are excited to see how our customers respond to the latest innovations and hear from them how we are solving their challenges” Benefits for Radiology Leaders and Decision Makers: Minimized risk of errorin reporting Improved workflow efficiency, leading to reduced burnout Faster reporting speeds, translating to greater practice performance Flexibility to scale and capture new revenue streams Technology that aligns with evolving best practices and reimbursement guidelines Join Us at RSNA 2025 - Shape the Future of Cardiovascular Imaging Nov. 30 – Dec. 3 | Booth #7961, North Hall Secure your demo now - see how cvi42 can help you lead with confidence and results.

Clinical Wins and Daily Practice Introduction A single cardiovascular imaging platform like Circle’s cvi 42 changes daily work for cardiologists and radiologists from “tool juggling” to focused clinical practice. But it also asks for effort and carries real, though manageable, risks. Seeing this change from your perspective, the people interpreting images and shaping programs, makes it easier to decide whether adopting a unified platform is worthwhile. What clinicians gain from one platform Less friction, more clinical time With one platform across MR, CT, structural heart, and EP: You spend less time deciding which tool to open and more time deciding what the data means. One login, one interface, and one workflow logic govern all modalities. Measurements, annotations, and reports behave consistently, so you aren’t constantly switching “UI languages.” AI and automation (e.g., contours, plaque, TAVR workflows) are applied the same way regardless of scanner or modality. This creates cognitive ease, a predictable environment where your brain can focus on nuance and complex decisionmaking instead of navigation. Better consistency and confidence A single platform builds one mental model for cardiac data: acquisition, processing, quantification, and reporting. Standardized protocols and templates reduce variability between readers and sites. Quantification tools remain the same across cases, deepening expertise in one toolkit. Shared measurement formats simplify heartteam discussions and QA reviews. This strengthens diagnostic confidence and supports defensible, consistent decisions. Stronger positioning for advanced and reimbursed work With MR, CT, structural heart, and electrophysiology workflows unified: Advanced workflows (perfusion, strain, plaque) feel like natural extensions of current practice. New reimbursed features (like AIbased plaque quantification) integrate smoothly into routine CCTA reads. Research and innovation benefit from standardized, unified data exports. This positions programs to stay clinically advanced and financially competitive. Less burnout, more sustainable practice Fragmented tools mean more clicks, context shifts, and afterhours work. Integrating platforms can: Reduce duplicate actions via shared worklists and structured reporting. Lower cognitive load through interface consistency. Simplify coverage and crosstraining, so expertise isn’t isolated to one person. Behavioral science shows that reducing friction and restoring control is as important as cutting workload—key factors for preventing burnout. Stay tuned for Part 4: The Effort, Risks, and Why It’s Worth It. While the clinical and operational gains are clear, shifting to a single platform isn't "zero effort". In our final installment, we’ll have a candid discussion about the implementation valley—addressing common concerns like short-term slowdowns and vendor dependence—and show how these risks are mitigated to create a safer, fairer, and more transparent environment for everyone.

For years, the Coronary Artery Calcium (CAC) score has been the gold standard for a quick, non-invasive look at heart disease risk. It’s a vital tool that has helped millions of patients understand if they have "hardening of the arteries." But while a calcium score tells us that plaque is present, it only tells part of the story. As medical technology evolves, we are moving beyond simply identifying the presence of calcium to a much more detailed understanding of heart disease. With the advent of AI-enabled coronary plaque analysis, such as cvi42 | Plaque , patients and physicians now have access to a deeper level of insight that was previously impossible to achieve through standard screening alone. What is AI-Enabled Coronary Plaque Analysis? While a traditional calcium score measures the amount of mineralized (hard) plaque in your coronary arteries, AI-enabled plaque analysis looks at the "soft" or non-calcified plaque as well.

The Clinical Challenge & the cvi42 Solution Executive Summary Cardiovascular disease remains the leading cause of global mortality, yet diagnostic workflows remain fragmented. Traditionally, clinicians have been forced to navigate disconnected systems to assess a patient’s heart: one for anatomy (CCTA), another for function (CMR/Strain), and a third for vascular inflammation (PCAT/Plaque). This "siloed" approach creates diagnostic friction, increases costs, and delays life-saving interventions.

Clinical and Financial Wins that Scale From Single Platform to Strategic Advantage Clinicians, department heads, and executives each win differently from consolidation. Circle’s cvi 42 turns integration into tangible impact across MR, CT, structural heart, and electrophysiology programs. Why Circle’s platform stands apart For clinicians: Market-leading MR and CT tools in one workspace, with AI-driven workflows for function, tissue, plaque, and procedural planning—faster, reproducible reads and intuitive tools for edge cases. For department heads: Consistent multimodality workflows, research-grade quantification, and data exports supporting registries and AI projects. For finance leaders: Shared investment across MR and CT service lines, volumealigned pricing, and new reimbursable procedures like AIenabled coronary plaque analysis. 

The activation of Category I CPT code 75577 on January 1, 2026, has transformed the reimbursement landscape for AI-enabled coronary plaque analysis, such as Circle Cardiovascular Imaging's FDA-cleared cvi 42 . This FAQ addresses key questions on payers, coverage, coding, payments, opportunities, threats, and value-based care impacts to guide adoption in cardiovascular imaging practices that ultimately lead to commercial viability. For Circle Cardiovascular Imaging customers deploying cvi 42 for plaque analysis, the new CPT 75577 landscape means reliable revenue streams (~$900-1,000 per case) with expanded payer access, but it requires refined billing to navigate bundling and denials. Overall, it accelerates the ROI on cvi 42 by enabling onsite AI processing that captures professional and technical fees hospitals previously outsourced.

Why a Unified Cardiovascular Imaging Platform Wins

Decoding the Coronaries CAD-RADS, or the Coronary Artery Disease Reporting and Data System, is a standardized reporting system designed to enhance the communication of coronary artery disease (CAD) findings from imaging studies. CAD-RADS represents a significant step towards a more systematic and evidence-based approach to the management of CAD. By standardizing reporting, guiding clinical decisions, facilitating research, and improving risk stratification, CAD-RADS not only holds the potential to improve the clarity of communication between the diagnostician and the downstream physician, but at a larger scale, it could contribute significantly to better cardiovascular health outcomes across populations. 

Taking a tour of even some of the historical branches of coronary artery disease (CAD) research, should make any healthcare professional excited in anticipation of the synthesizing effect of emerging technologies, such as AI, in CAD diagnosis, treatment and prevention. History of Coronary Artery Disease Research and Diagnosis seems to predict a great leap forward  Coronary artery disease (CAD) is a leading cause of morbidity and mortality worldwide. While often thought of as a “modern disease”, Coronary Artery Disease is probably as old as humanity. In evolutionary terms, the complex effects of prolonged lack of oxygen to myocardial tissue - as a result of the reduced blood flow via the arteries that supply the heart itself - are likely as old as the structure and function of any hominid heart. Long before the terms "atherosclerosis" or "ischemia" were coined, humanity had already begun encountering the symptoms of coronary artery disease. Ancient Egyptian mummies have shown evidence of arterial calcification, suggesting that atherosclerosis – the buildup of atheroma within blood vessels – has existed for millennia. These calcified plaques, visible through modern imaging like CT and MR contrast-enhanced scans, tell a story of a disease that spans human history. The history of diagnosing and treatment of CAD is a fascinating journey reflecting advancements in medical understanding and technology. As is often the case, the various innovations serving as milestones on this journey say as much about the age in which they were introduced as they do about the disease they are attempting to diagnose or treat. For most of humanity's evolution and more recent sentient, recorded history, just from symptoms observed, the morbidity related to the functional “design” of our heart’s own plumbing must have been a terrifying (and perceived mostly as mind-bogglingly random) way to go. “If only we could recognize the signs earlier, predict the “attack” from early occurring symptoms” ...maybe then, we could prevent the seemingly random, sudden deaths resulting. This became the mantra, even the obsession of physicians and researchers focused on solving this puzzle. Starting from very caring, but only anecdotal observation, the inquisitive, but slow pattern-searching followed. Different branches of research began to take shape. Then, as in every other area of medical research, art gave way to science and through experimentation and innovation we started to make progress in researching the heart and the role of the coronary vessels as well. However, while each branch built on the conclusions of previous studies, the different areas of research have remained largely independent in approach and as a result, often stayed isolated in their progress as well. From Early Clinical Observations to Linking Symptoms to the Heart - The age of enlightenment and the honing of the scientific process: Historical medical texts, including those from ancient Greek and Chinese medicine, documented symptoms like chest pain, shortness of breath, and fainting – signs now often associated with CAD. While these early observations were often interpreted through mystical or humoral lenses, they laid the foundation for the clinical curiosity that would fuel centuries of cardiovascular research. Before any specific diagnostic tools existed, CAD was primarily recognized through its symptoms, most notably as chest pain. During the renaissance, anatomical discoveries through autopsies started to uncover the links between the structure of the heart and blood supply but the cause of angina remained too complex for the models of the age. William Heberden provided a detailed clinical description of angina pectoris in the late 18th century, linking it to exertion and emotional stress – further complicating the observed model. However, the underlying cause of narrowed coronary arteries wasn't fully understood. The Dawn of Objective Diagnosis (Early 20th Century): Early 1900s: Electrocardiogram (ECG):The excitement of the age about all things electric, predictably, was applied to cardiac research as well. The early 20th century introduced a transformative leap in cardiac diagnosis with the invention of the electrocardiogram by Willem Einthoven . This groundbreaking device allowed doctors to record the heart’s electrical activity - a revolutionary method that marked the first truly objective diagnostic cardiac exam. ECG allowed physicians to record the electrical activity of the heart and identify patterns indicative of myocardial ischemia and infarction. It also signaled the shift from just understanding to actually trying to do something about cardiac diseases. Visualizing the Arteries - Catheterization and Coronary Angiography: The magic of looking inside the human body without having to take it apart, through Wilhelm Roentgen’s X-rays, was obviously going to be aimed at the heart as well. The moment the technology moved from the hands of WWI military field-medics to routine practice in hospitals, the first cardiac fluoroscopy studies were also performed. The bizarre, self-experimentation story of first the cardiac catheterization was practically inevitable and also reflected the weirdness of the age between the world-wars. But, as Forssmann walked the stairs from the OR to the x-ray room a floor below with a catheter he inserted into his own right ventricle via his antecubital vein in 1929, (just wow!!) the practice of cardiology changed forever– the stunt proved that internal cardiac access was possible. The development of coronary angiography by Mason Sones by the late 1950s logically followed and, indeed, marked another significant leap in our understanding. The concept of injecting a contrast dye into the coronary arteries and taking X-ray images, allowed direct visualization of arterial blockages in real time and in-situ mapping of coronary arteries and their stenosis. Angiography quickly became the "gold standard" for definitively diagnosing the presence and extent of CAD, further improving our model of not only how a normal human heart tissue is structured and supplied with oxygen, but also showing how narrowing's and blockages in “this plumbing” result in the disease that can lead to potentially fatal clinical consequences. While our functional modeling and understanding of the disease took millennia, it took Dr. Sones less than a decade to move from the first coronary angiogram to the first coronary artery bypass graft (CABG) procedure. Expanding Diagnostic Capabilities in the late 20th and early 21st Centuries: Now that we had a clear model of CAD with a viable “fix”, the search was on to recognize it earlier, with decreasingly invasive procedures. The objective became to make the diagnosis more definitive and more predictive, while also reducing the risk from the diagnostic procedures themselves. At the same time, finding new patterns now visible from the combination of deploying the different diagnostic modalities that became available increased our understanding of the cause and the clinical risk from the extent and location of the stenosis. Stress Testing: Exercise electrocardiography (stress testing) gained prominence as a non-invasive way to provoke symptoms and ECG changes suggestive of CAD during physical exertion, combining clear anatomical understanding of heart function with the patterns of electrical activity. Prominence of Imaging: One unexpectedly positive legacy of the “nuclear age” – the medical use of isotopes for functional imaging was predictably applied to CAD diagnosis as well. Nuclear Cardiology techniques like myocardial perfusion imaging using radioactive tracers emerged to assess blood flow to the heart muscle under rest and stress conditions. The recognition of the negative effects of radiation necessitated the innovation of imaging while minimizing ionizing radiation. Ultrasound imaging of the heart became a valuable tool to assess heart function and sometimes visualize signs of ischemia. Combining ECG with ultrasound, stress echocardiography further enhanced CAD diagnostic capability. Computed Tomography Angiography (CTA) : As the age of analog instrumentation gave way to the age of digital signal processing and computers, CT imaging was born. In Cardiology, non-invasive, Computed Tomography Angiography(CTA) logically followed . In more recent decades, even though it is using x-rays, non-invasive CT angiography has become increasingly sophisticated, providing detailed 3D images of the coronary arteries without the need for catheterization in many cases. The near-ubiquitous access to CT scanners made cardiac CT (CCT) studies very common. The acquisition protocols have also evolved to better visualize lipid and calcium deposits, while quantitative analysis and standardized reporting of CAD continues to hold further great potential. Cardiac Magnetic Resonance Imaging (CMR ): Along with CCT, Cardiac MRI offers detailed information about heart structure and function and can be used to detect myocardial scar tissue and assess blood flow. Being a non-invasive, radiation-free imaging modality, CMR imaging is useful for the management of patients with CAD. Various MR acquisition techniques and protocols have been developed over the last three decades to evaluate cardiac function and detect defects in myocardial perfusion. Specifically, late gadolinium enhancement (LGE) imaging, a well-established technique that uses contrast to highlight scar tissue, can identify the presence and extent of scar tissue in the heart, which is a common finding in CAD. While CMR has a high degree of accuracy and reliability in detecting and characterizing CAD, the modality also allows accurate risk stratification of patients with established CAD. Post-processing and Reporting : While the amount of imaging studies and the corresponding imaging data has increased exponentially, the need for post-processing has also sky-rocketed, making automation necessary. Machine-learning techniques make it increasingly possible to minimize the manual effort required to not only accurately map the cardiac structure, function and blood-flow but to also to quantitatively analyze cardiovascular diseases, including CAD. Structured reporting’s adoption in cardiology is significantly ahead of other disciplines. Yet, only in the last decade have we started routinely categorizing and stratifying CAD , based on the extent of stenosis and overall plaque burden. Needless to say, quantified analysis and standardized reporting represent both a great downstream clinical value and a gold-mine of data for population-level analysis. Biomarkers for CAD : Another great branch of CAD research has been producing deeper understanding by identifying and utilizing various proteins, peptides and enzymes that are involved in CAD. Troponins, BNP, CRP, MPO, Lp(a) and IL-6– to name a few - each play a unique role in the diagnosis, risk assessment, and management of CAD. Troponins are considered the gold standard for diagnosing myocardial infarction (MI) and are highly sensitive and specific for cardiac injury. Elevated troponin levels can indicate ongoing ischemia and are used to assess the severity of CAD, often guiding decisions in emergency settings, triaging patients for further imaging or intervention. As research continues to evolve, these and other biomarkers may offer new insights into the pathophysiology of CAD. Labs now use highly sensitive assays to detect even minute changes, and AI-powered platforms hold the potential to synthesize this multifactor, often unstructured data into actionable clinical insights. Genetics and epigenetics - Unlocking Hereditary Risk : Recent studies have identified numerous genetic variants associated with CAD . Genome-wide association studies (GWAS) have pinpointed specific genes linked to lipid metabolism, inflammation, and vascular function. Some of these notable genetic markers associated with CAD have been studied extensively, including: PCSK9 : Variants in this gene can lead to elevated cholesterol levels, increasing CAD risk. LDLR : Mutations in the LDL receptor gene are linked to familial hypercholesterolemia, a condition that significantly raises the risk of CAD. APOE : The APOE gene is involved in lipid metabolism, and certain alleles are associated with increased CAD risk. Ongoing studies aim to discover more genetic variants and their functional implications . Additionally, advancements in gene editing technologies, such as CRISPR, hold promise for developing novel therapies that target the genetic basis of CAD. By leveraging genetic insights, healthcare providers will be empowered to routinely offer personalized care that addresses the unique risk factors of each patient. Present-Day Landscape: Merging Traditional and Tech-Driven Tools By now, in the early 21st century, we understand that Coronary Artery Disease occurs when the coronary arteries become narrowed or blocked, often due to atherosclerosis. Statistically, we have identified known risk factors, that include high cholesterol, hypertension, smoking, and diabetes. Nevertheless, CAD is a complex disease that varies in presentation and its exact progression in an individual remains difficult to predict. The biological mechanisms that lead to lipid deposits and calcification leading to the progression of the disease are relatively well understood. The less deterministic impact of family history, genetics and epigenetics is much less understood. Today, the diagnosis of CAD often involves a combination of the previously mentioned methods, tailored to the individual patient's symptoms, risk factors, and clinical presentation. Simple, diagnostic stress-ECG tests are most often used for initial evaluation followed often by modern, non-invasive imaging studies, such as an echo and cross-sectional imaging studies (CCTA or CMR), with coronary angiography reserved for cases requiring more definitive diagnosis or intervention. The field continues to evolve with ongoing research into new imaging and other diagnostic techniques, with each test carrying different advantages and disadvantages. Progress needs AI: The Case for Integration Overcoming Fragmentation in Research and Practice Progress is never a linear progression. Just like in other areas of cardiac research, and indeed all of medicine, of course, promising work is being done continuously in independent, but often diverging, sometimes even isolated areas of research. The practice of medicine organized into compartmentalized healthcare departments brings focus to sub-specialties, but, combined with the funding structure through grants, the deep and narrow areas of research often continue in silos without the benefit of broader perspectives. This fragmentation not only creates frustrating confusion for patients, it also limits healthcare’s ability to generate holistic, personalized care plans. It is high time to bring our historical learnings together – converging them, breaching conventional boundaries to improve cardiac research and care. Just like in other areas of life, we need to work to figure out how to bring AI to play a key role in integrating huge volumes of data and synthesize the information within various adjacent but seemingly independent scientific domains. AI doesn’t just process data- by analyzing diverse and large datasets, AI could potentially help predict coronary artery disease risk, develop personalized interventions for individual patients, effectively synthesizing knowledge from various biological, diagnostic and medical disciplines. AI also holds the potential to assist researchers by generating novel research hypotheses, detailed overviews, and experimental protocols based on a specified research goal for CAD research. AI could and should be harnessed to improve clinical practice diagnosis and subsequent management. Conclusion From the earliest symptom observations to today’s cutting-edge diagnostics, each era has added layers to our understanding of CAD. Can't wait to see what yet unpredictable benefits the age of AI will bring to the deepening of our understanding, assessment ultimately to the treatment of this pervasive condition. It is exciting to imagine what the ever-expanding pattern-search, pattern recognition, and modeling capabilities of even narrow-AI algorithms will bring to the table in terms of personalized risk assessment from multifactor quantified analysis, early screening, based on genetic and epigenetic risk factors, incidental findings from non-cardiac intended chest studies, and more. Maybe, just maybe,…we are on the cusp of bringing many possible angles of research, population health and diagnostic techniques together to make them quantified enough to bring these new, learning, modeling, intelligent tools to bear early enough for tackling CAD prevention- not just for an individual patient but for an at-risk population segment. To learn more about how AI-based CCTA post-processing can be part of your practice, visit www.circlecvi.com/cardiac-ct . As research continues to evolve, the integration of the many different “branches of research” into clinical practice supercharged by AI, will undoubtedly enhance our ability to prevent, diagnose and treat CAD, ultimately improving patient outcomes and reducing the burden of this prevalent disease. Frequently Asked Questions (FAQs) Q1. What are the most frequently used tests for diagnosing coronary artery disease? A combination of stress testing, cardiac CT angiography (CCTA), cardiac MRI, and biomarkers like troponin offers the highest diagnostic accuracy. Each test has unique advantages depending on patient risk profile. Q2. How can artificial intelligence improve CAD diagnosis? AI has the potential to improve CAD diagnosis by analyzing imaging, ECG, and lab datasets faster and with higher accuracy and consistency. It can help detect patterns in multi-modality datasets in the longitudinal health record of an individual patient, or can be an invaluable tool for analyzing large, multi-factor datasets across many patient groups. Q3. What role do genetics play in CAD? Genetics significantly affect CAD risk. Variants in genes like PCSK9, LDLR, and APOE can influence cholesterol metabolism, inflammation, and vascular function. Epigenetics further modify gene expression in the risk of CAD for a given patient. Q4. Can CAD be detected early without invasive procedures? Yes. Non-invasive imaging techniques like CT angiography, cardiac MRI, and stress testing, combined with biomarker analysis, can detect early signs of CAD without invasive catheterization. Given the general pervasiveness of CT for many different type of trauma or other clinical reasons for abdominal/chest CT acute studies, including additional quantitative analysis of CAD risk might carry significant value in the long run. Q5. What’s next for CAD diagnostics? Future diagnostics will rely heavily on AI, predictive modeling, and integration of multi-modal data including genomics, imaging, and lifestyle tracking. These advancements aim to enable early detection and prevention.